Cargando…

Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients

SIMPLE SUMMARY: Immune checkpoint blockers (ICBs) have demonstrated durable anti-tumor responses in advanced non-small cell lung cancer (NSCLC). Despite progress in development of new predictive biomarkers, such as PD-L1 expression, TMB, or MSI, there is still an urge for a better selection of patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Ning, Moreno-Manuel, Andrea, Calabuig-Fariñas, Silvia, Gallach, Sandra, Zhang, Feiyu, Blasco, Ana, Aparisi, Francisco, Meri-Abad, Marina, Guijarro, Ricardo, Sirera, Rafael, Camps, Carlos, Jantus-Lewintre, Eloísa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231221/ https://www.ncbi.nlm.nih.gov/pubmed/34204662 http://dx.doi.org/10.3390/cancers13122950

Ejemplares similares

MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value
por: Gallach, Sandra, et al.
Publicado: (2017)

MicroRNAs: Promising New Antiangiogenic Targets in Cancer
por: Gallach, Sandra, et al.
Publicado: (2014)

Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
por: Zhang, Feiyu, et al.
Publicado: (2021)

Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer
por: Duréndez-Sáez, Elena, et al.
Publicado: (2022)

CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
por: Moreno-Manuel, Andrea, et al.
Publicado: (2020)

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers
por: Usó, Marta, et al.
Publicado: (2016)

Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer
por: Herreros-Pomares, Alejandro, et al.
Publicado: (2019)

Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer
por: Puchades-Carrasco, Leonor, et al.
Publicado: (2016)

Potential Non-Invasive Biomarkers for Early Diagnosis of Oral Squamous Cell Carcinoma
por: Dikova, Valentina, et al.
Publicado: (2021)

Exosomal microRNAs in non-small cell lung cancer
por: Duréndez-Sáez, Elena, et al.
Publicado: (2021)

Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies
por: Palanca-Ballester, Cora, et al.
Publicado: (2021)

Identification of TRPC6 as a possible candidate target gene within an amplicon at 11q21-q22.2 for migratory capacity in head and neck squamous cell carcinomas
por: Bernaldo de Quirós, Sandra, et al.
Publicado: (2013)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

Biological insights in non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy
por: Abbas, Hussein A., et al.
Publicado: (2021)

On the Oral Microbiome of Oral Potentially Malignant and Malignant Disorders: Dysbiosis, Loss of Diversity, and Pathogens Enrichment
por: Herreros-Pomares, Alejandro, et al.
Publicado: (2023)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade
por: Yan, Cihui, et al.
Publicado: (2022)

Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer
por: Molina-Pinelo, Sonia, et al.
Publicado: (2016)

A T cell repertoire timestamp is at the core of responsiveness to CTLA-4 blockade
por: Philip, Hagit, et al.
Publicado: (2021)

Greater extent of blood‐tumor TCR repertoire overlap is associated with favorable clinical responses to PD‐1 blockade
por: Aoki, Hiroyasu, et al.
Publicado: (2021)

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
por: García-Foncillas, Jesús, et al.
Publicado: (2018)

TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients
por: Villalba, Maria, et al.
Publicado: (2019)

Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy
por: Aversa, Ilenia, et al.
Publicado: (2020)

Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
por: Villalba, Maria, et al.
Publicado: (2019)

A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
por: Tondini, Elena, et al.
Publicado: (2019)

Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy
por: Cardinale, Antonella, et al.
Publicado: (2021)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

PD-1 expression conditions T cell avidity within an antigen-specific repertoire
por: Simon, Sylvain, et al.
Publicado: (2015)

Combined chemoradiotherapy and programmed cell death‐ligand 1 blockade leads to changes in the circulating T‐cell receptor repertoire of patients with non‐small‐cell lung cancer
por: Someya, Masanori, et al.
Publicado: (2022)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization
por: Gee, Julia MW, et al.
Publicado: (2003)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade
por: Eissler, Nina, et al.
Publicado: (2016)

Clonal replacement of tumor-specific T cells following PD-1 blockade
por: Yost, Kathryn E., et al.
Publicado: (2019)

PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment
por: Le, Catherine T., et al.
Publicado: (2020)

Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
por: Davies, John S, et al.
Publicado: (2022)

Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
por: Yue, Chunyan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g72r1fgv0on4mahe7buq2mnbfv